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ABSTRACT 
Bacterial phosphoinositide-specific phospholipases C (PI-PLCs) are the smallest 
members of the PI-PLC family that includes much bigger mammalian enzymes 
responsible for signal transduction as well as enzymes from protozoan parasites, yeast 
and plants. Eukaryotic PI-PLCs have calcium in the active site, but this is absent in 
the known structures of gram-positive bacteria where its role is instead played by 
arginine. In addition to their use in a number of industrial applications, the bacterial 
enzymes attract special interest because they can serve as convenient models of the 
eukaryotic enzymes catalytic domains for in vitro activity studies. We report here the 
structure of a PI-PLC from Pseudomonas sp-62186, the first from a gram-negative 
bacterium and the first of a native bacterial PI-PLC with calcium present in the active 
site. Solution of the structure posed particular problems owing to the low sequence 
identity of available homologous structures. Dependence on calcium for catalysis 
makes this enzyme a better model for studies on the mammalian PI-PLCs than 
previously used calcium-independent bacterial PI-PLCs.  
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INTRODUCTION 
Phospholipases of type C (PLC) cleave phospholipids on the diacylglycerol side of 
the phosphodiester bond. Members of the phosphoinositide-specific phospholipase C 
(PI-PLC) family catalyse the cleavage of the membrane lipid phosphatidylinositol 
(PI), or its phosphorylated derivatives, releasing diacylglycerol and (phosphorylated) 
myo-inositol. PI-PLCs have been isolated from plants, mammals, yeast, protozoan 
parasites and bacteria, reviewed in (Griffith & Ryan, 1999, Katan, 1998). In plants, 
they are involved in lipid signalling, regulation of growth and development, and 
response to nutrient deficiency as well as biotic and abiotic stress (Singh et al., 2015). 
In eukaryotes, they cleave more highly phosphorylated forms of PI forming myo-
inositol 1,4,5-trisphosphate (Ins 1,4,5-P3) and diacylglycerol, which act as second 
messengers in a number of receptor-mediated signalling pathways (Suh et al., 1988, 
Rhee et al., 1989, Majerus et al., 1986, Cocco et al., 2015). In gram-positive bacteria, 
they have been proposed to contribute to virulence (Heinz et al., 1995), although 
direct evidence of their role in pathogenicity is unclear (White et al., 2014). PI-PLCs 
are also found in non-pathogenic gram-positive bacteria (Griffith & Ryan, 1999).   
All PI-PLCs belong to the PI-PLCc_GDPD_SF (catalytic domain of 
phosphoinositide-specific phospholipase C-like phosphodiesterases superfamily, 
accession cl14615) superfamily in the NCBI Conserved domains database, CDD 
(Marchler-Bauer et al., 2015), together with several other enzyme families e.g. 
glycerophosphodiester phosphodiesterases (GP-GDE), which all share a similar 
mechanism of general base and acid catalysis with conserved histidine residues and 
hydrolyze the 3'-5' phosphodiester bonds in different substrates. The active site 
features relevant to PI-PLCs and the reaction mechanism will be discussed in more 
detail below. Briefly, the catalytic domain fold is a (ȕĮ)8, TIM barrel, with conserved 
active site residues belonging to one half of the barrel (termed the X-box for the 
mammalian PI-PLCs (Rhee et al., 1989)), and the second half responsible for the 
specificity towards different ligands. 
There are 13 isoforms of mammalian PI-PLCs identified to date, belonging to 6 
families: PLCE, J, į, H, ] and K, with specific isoforms being linked to specific 
signalling pathways. The best studied isoform for which structural information is 
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available, is PI-PLCį from rat (Essen et al., 1996), which will be used in structure 
comparisons here. All isoforms have four domains in common (with the additional, 
different domains present for some, depending on their specific functions): a 
pleckstrin homology domain (PH) involved in membrane binding, an EF-hand 
domain (with EF-hand calcium binding motifs, but most probably not linked to 
calcium regulation in PLCs), a catalytic domain ((ȕĮ)8, TIM barrel), and a ȕ-sandwich 
C2 domain (named after the second conserved domain of protein kinase C, with a 
possible role in orientation of the catalytic domain relative to the membrane) (Bunney 
& Katan, 2011, Fukami et al., 2010, Williams, 1999). It has been speculated that the 
bacterial enzymes evolved from eukaryotic PI-PLCs, losing the additional domains 
and optimizing the catalytic domain for PI cleavage (Heinz et al., 1998). Indeed, 
bacterial PI-PLCs exhibit significant structural similarity to the catalytic domain of 
mammalian PI-PLCs (Heinz et al., 1998, Essen et al., 1996), and are viewed as 
convenient model systems for these more complicated eukaryotic signalling 
molecules (Griffith & Ryan, 1999). Until recently, the most significant and consistent 
difference was the presence of an essential, catalytic calcium in the eukaryotic 
enzymes and its replacement by arginine in all known bacterial structures.   As 
bacterial cell membranes do not normally contain PI (Bishop et al., 1967, Ames, 
1968), it was proposed that bacteria may use PI-PLCs for interaction with (higher) 
eukaryotic organisms (Smith et al., 1995, Goldstein et al., 2012, Marques et al., 1989, 
Zhao et al., 2013, White et al., 2014). While eukaryotic enzymes need calcium for 
fine-tuning signal transduction, the bacterial enzymes are thought to have evolved to 
use arginine instead of calcium to allow them to act in the intracellular space after 
uptake by the host cell where calcium levels are normally low. 
Crystallisation of a calcium-dependent PI-PLC from Streptomyces antibioticus 
(SanPI-PLC) (Jackson & Selby, 2012) was reported earlier, but while the structure 
was deposited in the PDB in 2010 (codes 3H4X and 3H4W), there is no associated 
publication. The purification of SanPI-PLC was reported and its calcium dependence 
identified (Iwasaki et al., 1994). The calcium dependence was subsequently 
confirmed and sequence alignments showed that the enzyme had calcium-binding 
residues corresponding to those of the eukaryotic enzymes as well as two catalytic 
histidines (Iwasaki et al., 1998, Zhao et al., 2003). Inspection of the structure reveals 
that while there is no calcium ion in the deposited PDB file, this enzyme potentially 
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has calcium-binding residues instead of an arginine in the active site. However, recent 
research has shown that the reaction mechanism of SanPI-PLC proceeds in an unusual 
way with the enzyme capable of cleaving a number of PI analogues, so the exact 
natural substrates of SanPI-PLC are still to be confirmed (Bai et al., 2010). 
All bacterial PI-PLC structures available from the PDB to date have been from gram-
positive bacteria, and none of them are calcium-dependant. The only other bacterial 
PI-PLC for which a structure with an active site calcium has been reported is that 
from Bacillus thuringiensis (PDB code 1T6M), which has an engineered calcium 
binding site resulting from an R69D mutation (Apiyo et al., 2005, Kravchuk et al., 
2003). We report here the first structure of a wild type PI-PLC from the gram-
negative bacterium Pseudomonas sp-62186, with calcium clearly identified in the 
active site in both the apo form and in complex with myoinositol. This makes an 
interesting update to an established PI-PLC classification. 
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EXPERIMENTAL 
Cloning, expression, purification and activity assay  
The PsPI-PLC gene was inserted into a Bacillus expression plasmid. The DNA 
encoding the mature polypeptide predicted by Signal P (Bendtsen et al., 2004) was 
cloned in frame to the Bacillus clausii secretion signal, BcSP, having the following 
amino acid sequence MKKPLGKIVASTALLISVAFSSSIASA replacing the native 
secretion signal sequence with an extra alanine at the C-terminus. This resulted in a 
recombinant mature polypeptide with an alanine in front of the N-terminus of the 
mature wild type sequence. The BcSP fused to the PI-PLC gene was expressed under 
control of a promoter system described in (Widner et al., 2000). Furthermore, the 
plasmid contained a terminator sequence and a gene coding for chloramphenicol 
acetyltransferase which was used as a selection maker as described in (Diderichsen et 
al., 1993) for Bacillus subtilis. The E-lactamase gene giving ampicillin resistance and 
the kanamycin resistance gene were used as cloning selection marker genes for 
Escherichia coli growth. The plasmid also contained an E. coli origin of replication.  
E. coli TOP10 cells were transformed with the plasmid and one clone containing the 
correct PI-PLC gene sequence was selected. Competent B. subtilis cells were 
transformed with the plasmid isolated from the selected E. coli clone containing the 
PI-PLC gene. The final expression plasmid integrated into the B. subtilis chromosome 
by homologous recombination into the pectate lyase gene locus. Chloramphenicol-
resistant transformants were analysed by PCR to verify the correct size of the 
amplified fragment. A recombinant B. subtilis clone containing the integrated 
expression construct was selected and cultivated on a rotary shaking table in 500 ml 
baffled Erlenmeyer flasks each containing 100 ml LB media supplemented with 34 
mg/l chloramphenicol. The clone was cultivated for 5 days at 30°C. The enzyme-
containing supernatants were separated from the cells by centrifuging the culture 
broth for 30 minutes at 15.000 x g and the enzyme was purified as described below. 
The supernatant from 1 l of culture broth (shake flasks) was filtered through a 0.22 
µm PES membrane and buffer-exchanged into 50 mM MES pH 6.5 using a packed 
bed of G-25 (Sephadex G-25 Medium, GE Healthcare). Collected fractions were 
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analysed by SDS-PAGE (NuPAGE® 4-12% Bis-Tris gel, reducing conditions) and 
pooled based on the presence of a band with the expected molecular weight (approx. 
33 kDa). The pool was loaded on a packed bed of Source 15S (GE Healthcare) and 
bound material eluted using a linear gradient. PsPI-PLC eluted at 50 mM MES, 0.15 
M NaCl pH 6.5 (in a gradient going from 0-0.5M NaCl (buffer A: 50 mM MES pH 
6.5; buffer B: Buffer A + 0.5 M NaCl) in 10 CVs. Collected fractions were analysed 
by SDS-PAGE and pooled based on the presence of a band with the expected 
molecular weight. The pool was concentrated 2-fold by use of centrifugal spinfilters 
(Vivaspin® 20, 10,000 MWCO PES, cat. No. VS2002, Sartorius AG) to a final conc. 
of approx. 3.5 mg/mL (based on A280, H280 =1.7 ml*mg-1*cm-1). 
For the activity assay, the enzyme was diluted to 0.9 and 0.09 mg/mL in 100 mM 
citrate buffer, pH 4.0, 5.5 and 7.0. Crude soybean oil (0.25 ml) was pipetted into 2 ml 
Eppendorf tubes to which the diluted enzyme (25 µl) was added. This resulted in 
reactions with 10 and 100 mg enzyme per kg oil, 10% water, at pH 4.0, 5.5 and 7.0. 
The mixtures were incubated in a thermoshaker at 50°C for 2 h. Then adding 0.500 
mL internal standard solution (IS, 2 mg/mL triphenyl phosphate in methanol), 0.5 ml 
chloroform-d (CDCl3) and 0.5 ml Cs-EDTA buffer (0.2 M EDTA adjusted to pH 7.5 
with CsOH). Phase separation was obtained after 30 s shaking followed by 
centrifugation (3 min, 13,400 rpm). For each reaction as well as a blank (no enzyme), 
the lower phase was transferred to a NMR tube with a pipette and the 31P NMR 
spectrum was recorded using a 400 MHz Bruker Avance-III HD instrument, operating 
at 300 K, with 128 scans, 5 s relaxation delay. All signals were integrated. Chemical 
shifts were approx. 1.7 ppm (PA), -0.1 ppm (PE), -0.5 ppm (PI), -0.8 ppm (PC), -17.8 
ppm (IS). The concentration of each phospholipid class was calculated as "ppm P", 
i.e. mg elemental Phosphorus per kg oil sample. Hence, ppm P = I/I(IS) * n(IS) * 
M(P) / m(oil). 
Crystallization  
Native protein 
Prior to crystallization, the protein was further concentrated to 24 mg/ml by 
ultrafiltration in an Amicon centrifugation filter unit (Millipore), aliquoted to 50 µl 
and aliquots that were not immediately set up for crystallization were flash frozen in 
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liquid nitrogen and stored at -80°C to use later in optimizations/complex formation. 
The buffer was not changed from the ion exchange elution conditions 50 mM MES, 
0.15 M NaCl pH 6.5. Crystallization screening was carried out using sitting-drop 
vapour-diffusion with drops set up using a Mosquito Crystal liquid handling robot 
(TTP LabTech, UK) with 150 nl protein solution plus 150 nl reservoir solution in 96-
well format plates (MRC 2-well crystallization microplate, Swissci, Switzerland) 
equilibrated against 54 µl reservoir solution. Experiments were carried out at room 
temperature with a number of commercial screens. Initial crystals were obtained in 
PACT premier HT-96 (Molecular Dimensions) condition H4 (0.2 M KSCN, 20% 
PEG 3350, 0.1 M BTP pH 8.5). These were optimised in 24-well Linbro trays 
(hanging drops) using an Oryx-8 robot (Douglas instruments, (Shah et al., 2005)), by 
microseeding with a range of seed dilutions and a fine pH grid (between pH 9-10). 
Seeding stock was prepared, and seeding carried out according to the published 
protocols (Shaw Stewart et al., 2011). Briefly, crystals from the initial successful drop 
were transferred on a glass slide, crushed, and collected in a Seed BeadTM (HR2-320, 
Hampton research) with 50 µl well solution added, vortexed for one minute, and used 
as an initial seeding stock. New seeding stock was prepared from the first 
optimisations. Different protein/well/seeds ratios (1/0.9/0.1, 1/0.99/0.01, 1/1/0; these 
are drop sizes in µl) were used for three hanging drops on one coverslip, in an 
automated set up using the Oryx8 robot. Unused seeding stocks were stored at -20°C 
for later experiments. The best crystals grew close to pH 10, in the PEG concentration 
range 24-27%, with 1:200 (1protein :0.99well :0.01seed) seed dilution.  
Myoinositol complex 
Myoinositol (Merck Millipore, catalogue number 104507, 99+%) was dissolved in 
water to make a 500 mM stock. This was mixed with the protein, 40 µl protein + 
10 µl myoinositol, to give a final concentration of 100 mM.  Crystals were obtained 
by seeding with native protein crystallization stock, in hanging drops with varying 
protein-to-well solution ratios, using the Oryx-8 robot, under conditions similar to 
those giving native crystals. No back-soaking was carried out, but the excess 
myoinositol was possibly removed during cryoprotection.  
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Data collection, structure solution and refinement 
Computations were carried out using programs from the CCP4 suite (Winn et al., 
2011), unless otherwise stated. The final models were validated with MOLPROBITY 
(Chen et al., 2010). Data processing and refinement statistics for all three structures 
are provided in Table 1. In the text below and in Figures 2 and S1, the structure with 
the smaller unit cell (a = b § 96 Å) is referred to as Form 1, and that with larger unit 
cell (a = b § 135 Å), both apo and with bound ligand, is referred to as Form 2. 
Native structure 
Data were collected for two crystal forms at the Diamond Light Source and processed 
with Xia2 (Winter et al., 2013), Table 1. Data for Form 1 were processed to a 
resolution limit of 1.46 Å in point group 422 and P-lattice with unit cell dimensions 
of a = b = 96.1 Å and c = 113.3 Å, which suggested either one molecule (solvent 
content of 69%) or two (38.5%) in the asymmetric unit. The second possibility was 
confirmed since a strong non-origin peak in the Patterson synthesis at (0.50, 0.50, 
0.48) indicated two-fold pseudotranslation. The low solvent content implied potential 
problems for molecular replacement in addition to those associated with the presence 
of pseudotranslation. Data to 1.7 Å resolution were used in molecular replacement 
and to 1.5 Å in the final refinement. 
The first search model was generated with Sculptor (Bunkoczi & Read, 2011) from 
PDB entry 3h4w (sequence identity 27%). Sculptor option 1 was selected to provide 
maximum truncation of the input model, but nevertheless Phaser (Mccoy et al., 2007) 
rejected all the putative solutions because of clashes. Moreover, there were no 
solutions which stood out before the rejection, with the Log Likelihood Gain (LLG, 
difference between the log-likelihoods for a given model and unrelated models) 
varying from 27 to 29 for several top solutions, well below the value of 120 that is 
considered as an almost certain indication of a correct solution. 
There are several pipelines currently available which try various protein fragments or 
highly truncated homologous structures as search models and then try to extend such 
partial solutions through density modification and model building. Before undertaking 
such time consuming calculations, an attempt was made (and turned out to be 
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successful) to apply this approach at a much simpler level, with a single truncated 
model, which was manually prepared using COOT (Emsley et al., 2010) from the 
3h4w search model. The truncated model contained helices 90-105 and 133-144, 
strands 45-51, 114-122 and 183-190, and several adjacent residues (helices 2 and 3, 
and strands II, III and IV of the X-box; the total of 72 residues out of 298 in the target 
sequence) which seemed to form the most compact fragment of the molecule. 
PHASER now positioned two tNCS-related copies of this model with a LLG of 52 
compared to 44 and 42 for the second and third solutions. The best solution confirmed 
the space group to be P4322. A straightforward attempt to rebuild the MR solution 
using Buccaneer failed: the resulting R/R-free = 0.49/0.53 for 493 out of 596 residues 
built indicated incorrect main-chain tracing or sequence assignment. In order to 
generate a better starting model, two copies of a complete molecule from 3h4w were 
superposed using COOT on the two truncated copies positioned by PHASER. The 
complete molecules packed almost perfectly, with only one loop being too close to a 
neighbouring molecule thus providing strong evidence that the MR solution was 
correct. The model consisting of complete homologous molecules was rebuilt with a 
procedure involving refinement with REFMAC5 (Murshudov et al., 2011) and 
removal of incorrect fragments (total 300 cycles of refinement, final R/R-free = 
0.50/0.53 against all data), density modification with SHELXE (8 cycles, final CC of 
48%), refinement with REFMAC5 (24 cycles, R/R-free = 0.42/0.44), model extension 
and sequence docking with BUCCANEER (R/R-free = 0.25/0.28, 592 residues) and 
final refinement and model correction (R/R-free = 0.13/0.17). 
For crystal Form 2, diffraction images were merged using Xia2 to a resolution of 
1.17 Å. Molecular replacement with the model from Form 1 using MOLREP 
identified four monomers per asymmetric unit, all related by pseudotranslation. 
Manual rebuilding with COOT and refinement with REFMAC5 resulted in a model 
with R/R-free of 0.12/0.14 and 92.5 % residues built.  
Myoinositol complex 
Data were collected at DLS, and processed using XDS (Kabsch, 2010) in space group 
P43212, to a resolution of 1.45 Å. The structure was essentially isomorphous to the 
native Form 2 and was solved by MR with MOLREP using that structure as search 
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model. Refinement was performed using REFMAC5 and manual model 
building/correction in COOT. 
Sequence alignments and structure superpositions 
Sequence alignments and structure superpositions were carried out using ClustalX 
(Larkin et al., 2007) and SSM (Krissinel & Henrick, 2004) as implemented in 
CCP4mg  (McNicholas et al., 2011), respectively. The results are summarised in 
Table 2. 
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RESULTS AND DISCUSSION 
Cloning, expression, purification and assay 
The gene encoding the PsPI-PLC was amplified by PCR from genomic DNA of the 
bacterium Pseudomonas sp-62186, isolated from a seaweed sample collected in 
Denmark. Sequencing of 16S rRNA from the Pseudomonas species revealed 99.7% 
identity to Pseudomonas protegens CHAO (EMBL:CP003190). The PsPI-PLC gene 
was cloned, expressed in Bacillus subtilis, and purified as described under 
Experimental. The sequence of the gene coding for the PI-PLC from Pseudomonas 
sp-62186 was deposited in GenBank with the accession number GenBank:KY078744. 
To assay activity and substrate specificity, the purified enzyme in citrate buffer was 
incubated with crude (non-refined) soybean oil having a natural content of 
phospholipids. Assay conditions hence resemble those used in enzymatic plant oil 
degumming (De Maria et al., 2007). Following an aqueous extraction, the content of 
non-hydrolyzed phospholipids was characterized and quantified by 31P NMR 
spectroscopy. This sample preparation was inspired by reports documenting that 
extraction with aqueous EDTA leads to sharper phospholipid NMR signals (Yao & 
Jung, 2010). The result (Fig. 1) provided information about the enzymes pH activity 
profile and substrate specificity. As expected, the enzyme is highly specific towards 
PI and prefers neutral over acidic conditions. 
Pseudo-symmetry in the two crystal forms 
Figure 2 (a) illustrates the relation between the symmetries of the two crystal forms, 
and demonstrates that the diagonal screw-twofold axes in Form 1 (a = b § 96 Å) 
become a coordinate screw two-fold axes in Form 2 (a = b § 135 Å). Accordingly, the 
HM-symbols for the two space groups are different, P4322 and P43212, respectively. 
The situation is further complicated by the presence of a pseudo-translation in Form 
1, which acts as a second pseudo-translation in Form 2, and results in additional 
rotational pseudo-symmetry elements in both forms. The latter elements coincide in 
the two forms and are not shown in Figure 2 (a). As was shown using the Zanuda 
program (Lebedev & Isupov, 2014), the pseudo-symmetry space group (the group that 
includes all crystallographic symmetry elements and all pseudo-symmetry elements) 
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for both structures is I4122 with unit cell dimensions as in Form 1. As outlined in the 
next paragraph, the space groups realized in each of the two forms presents one of 
four possible ways of breaking I4122 symmetry to obtain a tetragonal space group 
with a P-cell (Form 1) and a tetragonal space group with twice larger P-cell (Form 2). 
In particular, the actually existing and presented in Fig. 2 (a) subgroup-supergroup 
relation between forms 1 and 2 is not a priori imposed by the approximate I4122 
pseudo-symmetry or by the point-group symmetry of the diffraction data and the 
systematic absences. 
Figures 2 (b, c) show the Patterson peaks and thus illustrate the pseudo-translations in 
the two crystal forms. There are four possible crystallographic space groups (P4122, 
P41212, P4322 and P43212) for pseudo-symmetry space group I4122 provided that the 
crystallographic translation base vectors are a, b and c, and (a + b + c)/ 2 is a pseudo-
translation (as in Form 1). There is intensity modulation for reflections k = l = 0 for 
Form 1 (Fig. S1 (a)), which, however, are not true systematic absences because the 
intensities of the most weak reflections with h = 2n + 1 nevertheless significantly 
exceed their experimental uncertainties (Fig. S1 (c)). This observation reduces the 
number of possible space groups to two (P4122, P4322). Similarly, there are four 
possible space groups (HM symbols P4122, P41212, P4322 and P43212) for the 
pseudo-symmetry space group I4122 with crystallographic translation base vectors a' 
= a + b, b' =  a + b and c' = c (as in the large-cell Form 2). Two of these (HM 
symbols P41212 and P43212) are consistent with the clear systematic absences k = l = 
0, h = 2n + 1 in the Form 2 data (Fig. S1b, d). During the structure determination, the 
remaining ambiguity (enantiomorphic space groups) was resolved at the molecular 
replacement step (Form 1: highest Phaser LLGs of 52.5 for the correct space group 
P4322 and 36.5 for the incorrect P4122; Form 2: highest Molrep's CCs of 0.269 for 
the correct and 0.259 for the incorrect) and this space group assignment was 
confirmed by low R-factors (below 0.2) and clear electron density maps for the 
refined structures. 
Overall fold and comparison to other PI-PLCs 
Like the structures of other bacterial PI-PLCs reported to date, PsPI-PLC forms an 
imperfect (EĮ)8 TIM-barrel (where TIM stands for triose phosphate isomerase 
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(Banner et al., 1975)); bacterial PI-PLCs are family 51699 in the SCOP database 
(Andreeva et al., 2008). As for other bacterial PI-PLCs, some of the E-strands are 
longer, and some shorter than in a canonical (ȕĮ)8 barrel (Moser et al., 1997, Heinz 
et al., 1995), which gives the barrel an irregular shape. In addition, the Į-helices are 
distributed around the barrel in an irregular way, with most clustered on one side. 
However, in contrast to other bacterial PI-PLC structures, there are connecting D-
helices between strands IV and V, and V and VI, and the E-barrel itself is more 
closed, while the C-terminal D8 helix is absent in PsPI-PLC (Fig. 3, 5). Furthermore, 
PsPI-PLC has two additional short antiparallel ȕ strands IIb, between II and III, and 
VIIIb, close to the C-terminus.  
X-ray structures of five bacterial PI-PLCs are available from the PDB from Bacillus 
cereus (BcPI-PLC), Bacillus thuringiensis (BtPI-PLC), Listeria monocytogenes 
(LmPI-PLC), Staphylococcus aureus (SauPI-PLC) and Streptomyces antibioticus 
(SanPI-PLC); PDB codes for representative structures are given in Table 2. The 
sequence identity of PsPI-PLC to the closest homologue, SanPI-PLC, is only 27.1%, 
and this made molecular replacement a challenge. Comparison of the overall fold for 
PsPI-PLC and SanPI-PLC is shown in Fig. 4 (a) together with the outline of the final 
model. The sequence identity is even lower, between 15.7-18.4% (Table 2), for the 
other bacterial homologues. Nevertheless, the active sites superimpose relatively well, 
with the ligand in the structures of complexes occupying essentially the same location 
(Fig. 4. (a), (b), (c)). In addition, the bacterial sequences have a degree of similarity to 
the X-box regions of the catalytic domains of eukaryotic PI-PLCs; the name X and Y 
boxes was given to the N- and C-terminal parts of the split (DE)8 barrel (Rhee et al., 
1989). While the sequence identity is low (between 13.9 and 19.7% for the X-box and 
bacterial PI-PLCs from the above list), the catalytic histidines are conserved. 
Moreover, the calcium-binding residues Asn312, Glu341 and Gln343 from the X-box 
are present in both calcium-binding PI-PLCs (Fig. 5). This catalytic calcium-binding 
(or calcium-free, with arginine) motif has been described for the PI-PLC family in an 
overview of E-barrel proteins (Nagano et al., 2002). The structural similarity, as for 
the bacterial PLCs, is significant - the X-box of the rat enzyme (296-440; 1djx) 
superimposes well on the bacterial PI-PLC N-terminal half of the E-barrel. Similar to 
what has been described for non-calcium binding bacterial PI-PLCs (Heinz et al., 
1998), sequence conservation for the second half of the barrel, corresponding to the 
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Y-box of the mammalian enzyme, is very low, although a number of structural 
elements superimpose reasonably well (Figs 4, 5).  
Ligand binding site 
As for all TIM barrel proteins, the ligand binding site is formed by residues from the 
C-terminal regions of the E-strands plus the connecting loop regions, the so-called 
activity face at the C-terminal end of the (DE)8 barrel (Hocker et al., 2001, Nagano 
et al., 2002). As reported for other PI-PLCs (Essen et al., 1997), there are no major 
conformational changes upon ligand binding, with the average rmsd between the 
subunits of the complex and those of the native structures lying within the range of 
rmsd between the individual subunits of the native structures (5fyo: 0.142 Å, 5fyp: 
0.276 Å, 5fyr: 0.245 Å, 5fyo/5fyp: 0.233 Å; 5fyr/5fyo: 0.202 Å, 5fyr/5fyp: 0.220 Å). 
Myoinositol is coordinated by Asn27, Asn240, Asn189, Glu48, Arg260, three water 
molecules and most interestingly a calcium ion. Trp262 contributes to the ligand-
binding pocket. Asn27, Glu48, Asp50, Asp119, the O2 of myoinositol and a water 
molecule (Fig. 6 (a)), coordinates the calcium ion. His26 is 3.2Å from the O2 of 
inositol, equivalent to the catalytic His32 first described in BcPI-PLC (Heinz et al., 
1995). In PsPI-PLC Tyr283 has replaced Asp274, which was proposed as a second 
member of the catalytic triad in BcPI-PLC. While Asp274 in BcPI-PLC forms a 
hydrogen bond with the ND1 of His32 (equivalent to His26 in PsPI-PLC), stabilising 
its position for catalysis, Tyr283 possibly plays an equivalent role in making a 
stacking interaction. The inositol OH2 moiety was proposed to complete a catalytic 
triad. Another histidine, His70, occupies a similar, although not identical position to 
His82 in BcPI-PLC, with CE1 ~5.5Å from OH1 of inositol, and has been suggested to 
be essential for catalysis, protonating the leaving group. Histidines corresponding to 
His26 and His70 are conserved in all (including mammalian) PI-PLCs, and as 
mentioned in the Introduction, are present in all the PI-PLCc_GDPD_SF superfamily 
members. The reaction mechanism is described below. 
Active site comparisons 
Streptomyces antibioticus SanPI-PLC 
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As expected, the ligand-binding site superimposes closely on that of SanPI-PLC used 
as the molecular replacement model. However, a number of features are less similar 
than for the Bacillus or, more interestingly, rat enzymes. This is in agreement with 
reports that SanPI-PLC is an unusual bacterial PI-PLC (Iwasaki et al., 1994) being 
later identified as one of two independent PI-PLCs in S. antibioticus cloned by a 
shotgun approach (Iwasaki et al., 1998). This enzyme was described as eukaryotic-
like due to a number of characteristics, one of which was its dependence on calcium, 
in addition to its lack of activity on GPI-anchored proteins. Two structures of the 
native enzyme were deposited in the PDB in 2009 (3h4w, 3h4x) but no calcium ion 
was modelled in the potential calcium-binding site. Subsequently, an unusual 
mechanism for PI catalysis was proposed, with trans-1,6-cyclic myo-inositol 
phosphate (1,6-IcP) being formed as an intermediate step (Bai et al., 2009). In 
addition, SanPI-PLC was shown to be capable of cleaving a number of structural 
analogues of PI, with its role and natural substrates still under investigation (Bai et al., 
2010).  
The calcium binding residues Asn27, Glu48 and Asp50 are all present in SanPI-PLC 
(Fig. 5  sequence alignment, and Fig. 7 (a)). A numbering discrepancy should be 
mentioned here for clarity: the corresponding residues in SanPI-PLC would have been 
Asn17, Glu39 and Asp41 if numbered as for the mature protein excluding the signal 
peptide from the entry for the proenzyme in Uniprot, B3A043 (Zhao et al., 2003). In 
the deposited structure (3h4w, 3h4x) the numbering starts from the beginning of the 
expression tag, so adds 21 to the original numbering making these residues Asn38, 
Glu60 and Asp62. We use the PDB numbering here to facilitate structure comparisons 
for the reader. The fourth potential calcium-binding residue Glu129, corresponding to 
Asp119 in PsPI-PLC, is also present, although not exactly at the same location, but 
could still bind a calcium ion (Fig. 7 (a)).   
While the calcium-binding residues and catalytic histidines in SanPI-PLC 
superimpose reasonably well with corresponding residues in PsPI-PLC, the ligand-
binding site as a whole has considerable differences in architecture from PsPI-PLC as 
well as the Bacillus and mammalian enzymes, with a wider opening, possibly 
explained by a different reaction mechanism. In PsPI-PLC, Trp262 lines the binding 
pocket, making a stacking interaction with inositol. There are no equivalent residues 
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in SanPI-PLC at the corresponding location (Fig. 7 (a)). His236 could possibly take 
part in the lining of the binding pocket in SanPI-PLC. The other bacterial PI-PLCs 
have tyrosines involved in stacking with inositol, close to, but not exactly 
superimposing on Trp262 in PsPI-PLC (Fig. 7 (b)), and the rat enzyme also has a 
tyrosine at the corresponding location (Fig. 7c). In summary, the binding pocket of 
the Streptomyces enzyme has significant differences from those of PsPI-PLC and the 
Bacillus and rat enzymes discussed below. 
The Bacillus PI-PLCs  
BtPI-PLC is a bacterial enzyme in which a R69D variant was designed to engineer a 
calcium-binding site (Apiyo et al., 2005, Kravchuk et al., 2003), and was shown to be 
activated by calcium. The structure was determined only for the mutant, but the 
closely similar BcPI-PLC (PDB ID 1ptg) can be used to compare the calcium-bound 
mutant to a wild-type enzyme, with an active site arginine Arg69. BcPI-PLC has 96% 
sequence identity to BtPI-PLC only differing by eight amino acids, and was used for 
comparisons of the mutant with the wild-type enzyme (Apiyo et al., 2005). Here 
again, there is confusion with residue numbering  the authors refer to the BcPI-PLC 
numbering, even though the amino acids are numbered differently in the PDB entry 
1t6m. The BcPI-PLC numbering is used here for both Bacillus structures. Fig. 7 (b) 
shows that the Arg69 guanidinium group from BcPI-PLC superimposes well on the 
calcium ion from BtPI-PLC, which in turn is quite close to the calcium ion in PsPI-
PLC. The engineered calcium-binding residue Asp69 (result of the R69D mutation) is 
positioned between two calcium-binding residues of PsPI-PLC: Asp50 and Asp119. 
The other two residues involved in calcium coordination in BtPI-PLC - Asp33 and 
Asp67  superimpose well on Asn27 and Glu48 from PsPI-PLC. The myoinositol 
ligand is in a similar location to that in PsPI-PLC, further away from the calcium ion 
(or Arg69 guanidinium group) towards the exit from the binding pocket. Tyr200 is 
involved in stacking interactions with the ligand, similar to Trp262 in PsPI-PLC 
coming in from a different part of the protein chain. Asp198 of BcPI-PLC occupies a 
position very close to that of Trp262, making hydrogen bonds to OH3 and OH4 of the 
ligand. This again differs from PsPI-PLC, where the OH3 and OH4 of myoinositol 
are coordinated by Asn189, Asn240 and Arg260, which are all far away from Asp198 
(BcPI-PLC).  
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Rat PI PLC 
The ligand binding site of the rat PI-PLC catalytic domain (Essen et al., 1997) 
superimposes on that of the PsPI-PLC strikingly well, more closely than for the 
Bacillus enzymes or even SanPI-PLC. The calcium binding residues all superimpose 
almost exactly, with the exception of Asp119 in PsPI-PLC which is Glu390 in rat PI-
PLC. Nevertheless, the calcium coordinating OD2 from Asp119 in PsPI-PLC is in a 
very similar location to the Glu390 OE1 in rat PI-PLC. The calcium ions from the 
PsPI-PLC and rat PI-PLC structures superimpose very well, much better than the 
engineered calcium in BtPI-PLC (Fig. 7 (b), (c)). The ligand in rat PI-PLC is D-myo-
inositol-1,4,5-trisphosphate (Ins1,4,5-P3), which differs from the inositol (Ins) in the 
PsPI-PLC complex by three phosphates on positions 1, 4 and 5 of the inositol ring. 
This is a phosphatidyl-less substrate analogue for the mammalian enzymes, which 
cleave the head groups from more highly phosphorylated species than the bacterial 
ones. The order of substrate preference phosphatidylinositol-4,5-bisphosphate (PIP2) 
> phosphatidylinositol-4-phosphate (PIP) > PI; bacterial enzymes are only able to 
cleave PI. There are several ligand complexes in the PDB, but only 1djx is used for 
the comparisons here, since the others are very similar. The inositol ring of Ins from  
PsPI-PLC superimposes on that of Ins1,4,5-P3 even better than on Ins from BcPI-
PLC, (where the ligand is exactly the same).  A stacking interaction is provided by 
Tyr551, which is located closer to Phe262 from PsPI-PLC than the tyrosines in the 
Bacillus enzymes. There is no equivalent stacking interaction in SanPI-PLC at this 
location, probably because it binds different ligands and cleaves them by a different 
mechanism.  
Reaction mechanism 
For PI-PLCs, both bacterial (BcPI-PLC; (Heinz et al., 1995, Heinz et al., 1998),  and 
mammalian (rat PI-PLC; (Essen et al., 1996, Essen et al., 1997), substrate-assisted 
catalysis has been proposed, in which the 2-OH group of phosphoinositide acts as a 
nucleophile. His32 in BcPI-PLC is a general base, and His82 a general acid, donating 
the proton to the leaving group. For the mammalian (rat) PI-PLC the mechanism may 
differ in that His311 (analogous to His32) is too distant from 2-OH of inositol in all 
available structures of complexes with inositol phosphates, so a role in stabilizing a 
transition state has been suggested for this His, while the role of general base was 
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assigned to Glu341 (Ellis et al., 1998). In PsPI-PLC, His26 (analogous to His311 in 
rat PI-PLC and His32 in BcPI-PLC) is close enough to the 2-OH group of the inositol 
(3.2Å) and its role as general base in the first step of the reaction cannot be excluded. 
Otherwise the mechanism for PsPI-PLC should be similar to that suggested for the 
mammalian enzyme (Fig. 6 (b)), and the general base His26 (His311 in rat PI-PLC 
and His32 in BcPI-PLC) or Glu 48 (Glu341 in rat PI-PLC; no direct equivalent in 
BcPI-PLC) deprotonates 2-OH leading to its nucleophilic attack on to 1-phosphate 
group and formation of a cyclic intermediate. In this first step the oxygen of 1-
phosphate group becomes transiently coordinated to calcium. His70 (His356, His82) 
then acts as a general acid, protonating the diacylglycerol leaving group. In the second 
step of the reaction, the cyclic intermediate undergoes hydrolysis. At this step, the 
acid/base roles were suggested to be reversed, so, in PsPI-PLC, His70 (His356, 
His82) would activate a water molecule and His26 (His311, His32) or Glu48 
(Glu341) would become a general acid.  
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CONCLUSIONS 
A new member of the bacterial PI-PLC family, the first of its kind for a PI-PLC from 
a gram-negative bacterium, has been cloned, expressed, and its X-ray structure 
determined. It is only the second bacterial PI-PLC in which calcium binding has been 
reported, and the first where a calcium ion has been modelled in the structure. The 
presence of a catalytic calcium makes this new group of bacterial enzymes more 
suitable models for activity studies on catalytic domains of medically important 
mammalian PI-PLCs. However, for SanPI-PLC, recent publications report a cleavage 
mechanism distinct from the canonical one, namely, trans-cyclization involving 
formation of inositol 1,6-cyclic phosphate intermediate rather than cis-cyclization to 
form 1nositol 1,2-cyclic phosphate occurring for all other known phospholipases C 
(Bai et al., 2009, Bai et al., 2010). In addition, comparisons show that the ligand-
binding site of PsPI-PLC is strikingly close to that of the mammalian enzymes and 
less similar to those from the closest bacterial structures. Taking into account these 
factors, the Pseudomonas enzyme seems a better model for eukaryotic catalytic 
domain than SanPi-PLC. Besides serving as a model system for mammalian PI-PLCs, 
the PsPI-PLC structure provides insight into the gram-negative PI-PLCs.  
Finally, phospholipases, including PLCs, are used in a number of industrial 
applications e.g. in the baking, egg yolk and dairy industries, and in plant oil 
degumming (De Maria et al., 2007). Such enzyme-based procedures are much more 
environmentally friendly than chemical methods. The new structures give valuable 
information for further protein engineering to improve on the existing applications or 
create opportunities for the new ones.  
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FIGURE LEGENDS 
Figure 1. Content of phosphatidic acid (PA), phosphatidylethanolamine (PE), 
phosphatidylinositol (PI) and phosphatidylcholine (PC) in crude soybean oil before 
(blank) and after incubation with 10 mg/kg and 100 mg/kg PsPI-PLC, respectively, 
over 2 h at 50 °C at a range of pH. 
Figure 2. Subgroup-supergroup relation between crystal Forms 1 and 2. (a) Black and 
orange colours designate crystallographic symmetry and pseudo-symmetry elements, 
respectively, in the Form 2 crystal. All these elements are crystallographic symmetry 
elements in Form 1, which has to be rotated by 45° about c and translated by b/ 2 
from its standard setting for corresponding symmetry elements to overlay as shown. 
(Note that both diagonal pseudo-symmetry two-fold axes and diagonal 
crystallographic screw two-fold axes in Form 2 correspond to crystallographic 
coordinate two-fold axes in Form 1.) The black rectangle represents the unit cell in 
Form 2 and the orange rectangle represents the rotated and translated unit cell of 
Form 1. (b) Form 1 and (c) Form 2, the Patterson maps are coloured blue at 0.03 of 
the height of the origin peaks and the unit cells are shown as yellow rectangles. The 
full resolution range of the experimental data was used, and hence the Patterson peaks 
are narrower for Form 2 which diffracts to higher resolution. Peaks 1 and 1' are origin 
peaks and the heights of other peaks relative to corresponding origin peaks are 0.30 
for peak 2, 0.21 for peak 2' and 0.10 for peak 3'. All non-origin peaks are split along c 
and their fractional coordinates along c are 0.5±0.017 for peak 2, 0.0±0.005 for peak 
2' and 0.5±0.017 for peak 3'. Peaks that are not labelled are generated from equivalent 
peaks by crystallographic translations. Unlabelled images for (b, c) were obtained 
using COOT. 
Figure 3. Ribbon representation of the PsPI-PLC fold. The numbering of the E-
strands in the (DE)8 barrel is as for bacterial PI-PLCs (I to VIII), but the numbering of 
the helices is different because of their different arrangement. The helices are instead 
numbered similarly to rat PI-PLC (1-7), with numbers following that of the previous 
E-strand (1 after I, etc.); when there are several helices between two strands, they 
have the same number followed by a letter. There is a 310 helix between strands I and 
II (38-42), coloured in purple, with a number 1 in italics. Several very short 310 
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helices and E-strands are not shown. This and other structure figures were prepared 
using CCP4mg (McNicholas et al., 2011). 
Figure 4. Ribbon diagrams showing the superposition of PsPI-PLC complex with 
myoinositol (gold) on (a) apo SanPI-PLC (PDB code 3h4x; green, with the successful 
molecular replacement model highlighted in darker green, §2.3.1), (b) the BcPI-PLC 
complex with myoinositol (1ptg, purple) and apo BtPI-PLC with an engineered 
calcium site (1t6m, ice blue), (c) rat PI-PLC complex with D-myoinositol-1,4,5-
triphosphate (1djx; pink), the zoom-in showing details of the active site. 
Superposition was carried out as detailed in Table 2. 
Figure 5. Sequence alignment of PsPI-PLC with SanPI-PLC and rat PI-PLC, with 
calcium-binding residues (putative Ca binding for SanPI-PLC) and catalytic histidines 
outlined in green. Secondary structure elements are shown as symbols for PsPI-PLC 
and as background colours for the other two sequences. In both types of presentation, 
helices are red, 310 helices yellow and ȕ-strands violet. ClustalX (Larkin et al., 2007) 
and structure superpositions described in Table 2 were used for initial alignment of X-
boxes and its manual adjustment, respectively. The alignment for Y-boxes was 
obtained in a similar manner but required more substantial structure-based manual 
correction. The graphical representation of alignment shown here was prepared using 
the program ALINE (Bond & Schuttelkopf, 2009) 
Figure 6. Active site and reaction mechanism of PsPI-PLC. (a) Schematic 
representation of the hydrogen bonding in the active site. Dashed lines show potential 
hydrogen bonds made by the enzyme side chains to myoinositol, Ca2+ and water 
molecules; hydrogen bonds between the side chains are not shown. Bond distances 
(Å) are indicated for H-bonds involving myoinositol and Ca2+. Trp262, shown as a 
red arch, is involved in a stacking interaction with the myoinositol ring. His70 is not 
shown as it makes no H-bonds to the phosphate-free inositol in the PsPI-PLC 
structure, but it is shown in Fig. 7(c), where it occupies a very similar position to 
His356 of the superposed structure of the rat PI-PLC D-myo-inositol-1,4,5-
trisphosphate complex. (b) The detailed mechanism shown here was initially 
demonstrated for rat PI-PLC (Essen et al., 1996, Essen et al., 1997) and adapted for 
PsPI-PLC based on structural similarity between the mammalian and the bacterial 
enzymes. His26 (His311 in the mammalian enzyme) or Glu48 (Glu341) acts as a 
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general base and deprotonates the myoinositol OH-2 which then carries out a 
nucleophilic attack on the 1-phosphate group of the ligand resulting in a cyclic 
intermediate. The role of calcium is to stabilise the transition state, while His70 
(His356) acts as a general acid and protonates the diacylglycerol leaving group. Ɍhe 
cyclic intermediate undergoes hydrolysis in the reverse reaction with acid and base 
swapping their roles. LigPlot+ (Wallace et al., 1995) with a distance threshold of 3.3 
Å and ChemDraw (ChemDraw Prime 15.1, PerkinElmer) were used to generate (a) 
and (b) respectively. 
Figure 7. Comparison of the binding sites for the PI-PLCs. Stereo diagrams show 
superposition of the binding site of the PsPI-PLC complex with MI (gold) on the 
corresponding regions of (a) SanPI-PLC (3h4x, green), (b) the BcPI-PLC complex 
with MI (1ptg, purple) and the BtPI-PLC R69D mutant (1t6m, ice blue), and (c) the 
rat PI-PLC complex with D-myo-inositol-1,4,5-trisphosphate (1djx, pink). Protein 
residues are shown as cylinders, ligands as ball and stick, and calcium ions as spheres. 
Residues used in the superpositions belong to the X-box domains (Table 2). In all 
panels (a-c), the catalytic His26 and His70 of PsPI-PLC are in similar locations to 
their counterparts in the matched structures. The best alignment for His70 (general 
acid), is achieved in (c), in the superposition with the rat PI-PLC. The planes of His26 
(possible general base) in the PsPI-PLC structure and its counterpart (His311) in rat 
PI-PLC have different orientations, possibly because inositol is not phosphorylated in 
the former structure, while 1-phosphate is present and makes H-bond to His311 in the 
latter. In (c) Glu48 in PsPI-PLC is seen to align perfectly with Glu341 in rat PI-PLC 
(a candidate for the general base in the mammalian enzymes; Essen et al., 1997), but 
has no clear counterpart in the wild type bacterial enzymes (a, b). The difference in 
the position of the inositol O2 between PsPI-PLC and rat PI-PLC can be attributed to 
the lack of a 1-phosphate in the former. Ca2+ is present only in PsPI-PLC, rat PI-PLC 
and the BtPI-PLC R69D mutant and superposes most closely in the first two. Overall, 
the PsPI-PLC active site has more similarity to the active site of the rat enzyme (c) 
than the bacterial enzymes (a, b) suggesting a mammalian-like catalytic mechanism 
for PsPI-PLC. 
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TABLE 1.  
Crystallographic statistics. 
Data collection
(a)
 
Data set Native Form 1 Native Form 2 Myoinositol 
complex 
Beamline Diamond I03 Diamond I03 Diamond I03  
Wavelength (Å) 0.98 0.98 0.98 
PDB code 5fyo 5fyp 5fyr 
Space group P4322 P43212 P43212 
Cell parameters (Å) a=96.08 
b=96.08 
c=113.3 
a=135.21 
b=135.21 
c=112.47 
a=135.59 
b=135.59 
c=113.79 
Resolution range (Å) 48.81-1.5 
(1.53-1.50) 
67.61-1.17 
(1.20-1.17) 
48.93-1.45 
(1.47-1.45) 
Number of reflections 1097060 4032897 1334118 
Unique reflections 85192 346088 184175 
Monomers in asymmetric unit 2 4 4 
Completeness (%) 99.9 (100) 99.9 (99.8) 99.7 (95.9) 
¢I / ı(I)² 27.5 (4.8) 17.2 (2.5) 14.5 (2.5) 
CC1/2
 (b) 0.999 (0.938) 0.999 (0.733) 0.999 (0.786) 
Multiplicity 12.9 (12.4) 11.7 (4.8) 7.2 (5.7) 
Rmerge
 (c) 0.049 (0.535) 0.075 (0.531) 0.067 (0.595) 
Refinement statistics 
Fraction of free reflections 0.051 0.050 0.050 
Final Rcryst 0.125 0.116 0.144 
Final Rfreet 0.166 0.141 0.192 
R.m.s. deviations from ideal geometry (target values are given in parentheses) 
Bond distances (Å) 0.015(0.019) 0.013(0.019) 0.015(0.019) 
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Bond angles (°) 1.57 (1.92) 1.58 (1.92) 1.623(1.923) 
Chiral centres (Å3) 0.132 (0.200) 0.104 (0.200) 0.113(0.200) 
Planar groups (Å) 0.009 (0.021) 0.011 (0.021) 0.009(0.021) 
Average main chain B values (Å2) 21.9 10.1 14.6 
Average side chain B values (Å2) 25.1 12.6 17.6 
Average B values for Ca (Å2) 23.1 13.0 (occ=0.8) 16.1 
Average  B values for Ins (Å2) N/A N/A 13.8 
Molprobity score 0.83 0.87 1.1 
Ramachandran favoured (%) (d) 97.5 97.5 97.4 
Ramachandran outliers (%) (d) 0.2 0.1 0.1 
Clashscore 1.22 0.86 2.17 
a values in parentheses correspond to the highest resolution shell 
c CC1/2 values for Imean are calculated by splitting the data randomly in half 
b Rmerge is defined as Ȉ~I - <I>~/ Ȉ I, where I is the intensity of the reflection 
d Ramachandran plot analysis was carried out by MOLPROBITY (Chen et al., 2010) 
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TABLE 2 
Sequence and structure comparisons of PsPI-PLC with bacterial PI-PLCs and rat PI-
PLC. One representative structure per organism (liganded if available) was chosen for 
comparison with PsPI-PLC complex with Ins. Sequence identity with PsPI-PLC is 
shown for the full length bacterial enzymes and for the region including only X-box 
(300-440) and Y-box (487-606) of the mammalian (rat) PI-PLC. Structural 
alignments were conducted using SSM (Krissinel & Henrick, 2004) as implemented 
in CCP4mg (McNicholas et al., 2011) for the X-boxes only, which form the most 
conserved parts of the proteins and contain all the residues essential for catalysis. The 
table shows the input residue ranges and CĮ r.m.s.d.s reported by the program. The 
superposed structures were also used for manual adjustments of ClustalX sequence 
alignments (Fig. 5) and for generation of Figs. 4 and 7 showing superposition of the 
complete molecules and their active sites, respectively 
 
Species PDB 
ID 
ligand *) sequence 
identity to 
PsPI-PLC  
CĮ r.m.s.d. to 
PsPI-PLC, Å for 
the X-boxes (and 
input residue 
ranges)  
P.  sp-62186 5fyr Ins 1.000 0.00 (2-190)**) 
S. antibioticus 3h4x none 0.271 1.60 (25-223)**) 
B. thuringiensis 1t6m none 0.200 2.22 (5-162)**) 
B. cereus 1ptg Ins 0.185 2.25 (1-166)**) 
S. aureus 3v1h Ins 0.185 2.27 (7-166) 
L. monocytogenes 1aod Ins 0.158 2.15 (21-177) 
R. norvegicus 1djx I3P 0.206 2.10 (300-440)**) 
*) abbreviations for ligands: Ins  myoinositol, I3P  D-myoinositol-1,4,5-
triphosphate. 
**) structures shown in Fig. 4 and Fig.7 
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